Tamaricaceae

Other Names

suomi: TamariskikasvitTamaricacéesTamariscinaceaetamarisktamarisk familyTamariskengewächseTamariskfamilieTamariskfamilientamariskikasvittamariskväxterTamaryszkowateВрежовиԿարմրանազգիներიალღუნისებრნი柽柳科

Synopsis

Tamaricaceae: A Comprehensive Reference on the Tamarisk Plant Family as a Dietary Supplement and Natural Ingredient

1. Identity and Botanical Classification

1.1 Taxonomic Position and Family Overview

Tamaricaceae (order Caryophyllales) is a family of around 80 rheophytes, halophytes, and xerophytes grown in semi-arid and dry regions, especially in central and southwest Asia. More broadly, the family Tamaricaceae includes five genera: Hololachna (one species), Myrtama (one species), Reaumuria (22 species), Myricaria, and Tamarix (approximately 70 species). The Tamaricaceae family includes shrubs and trees that are halophytic, rheophytic, or xerophytic, have slender and flexuous branches, and prefer sandy and maritime habitats, steppes, and deserts.

The genus Tamarix in the Tamaricaceae family consists of more than 100 species of halophyte plants worldwide, which are mainly used to improve saline-alkali land and for coastal windbreaks, sand fixation, and afforestation in arid areas. The genus Myricaria, one of the secondary medicinal genera within Tamaricaceae, is described separately below.

1.2 Principal Genera and Medicinal Species

The genus most heavily studied for medicinal and supplemental uses is Tamarix. The genus Tamarix, known by the common names "tamarisk" and "salt cedar," consists of more than 60 species of halophyte plants grown in nearly all parts of the world. Prominently researched species include:

Tamarix aphylla (L.) Karst. (Athel pine, leafless tamarisk) — a well-known species of the genus Tamarix; a perennial tree in Asia, the Middle East, and Central Africa.
Tamarix gallica L. (French tamarisk, Jhau) — commonly known as "Jhau," a deciduous, twiggy shrub or small tree reaching up to about 5 meters high, mainly found in salty regions and interdunal areas of the desert.
Tamarix articulata Vahl. — a species studied for antioxidant, anticancer, and hepatoprotective activity.
Tamarix africana Poir. — studied in North Africa and the Mediterranean region for phenolic richness and antioxidant potential.
Tamarix chinensis Lour. — used in East Asian traditional medicine.
Tamarix nilotica (Ehrenb.) Bunge — studied for cytotoxic and anticancer properties.

Within Tamaricaceae, the genus Myricaria is also of medicinal interest. The genus Myricaria is one of the four genera within the Tamaricaceae family; it comprises 13 species distributed across Eurasia. The species Myricaria germanica (German false tamarisk) has received the most phytochemical attention within this genus.

1.3 Botanical Characteristics

These plants are characterized by needle-like leaves that are covered with salt, secreted from salt glands. Tamarisk species are well-known for their growth in hot and dry climates, but are also found in temperate climates. Tamarix species are cultivated in dry climates in order to fix sand dunes; their growth in wet climates is not always desired, as they can act as invasive plants that prevent the growth of other species.

1.4 Common Names and Synonyms

Across traditions and cultures, Tamarix species carry numerous vernacular names. The plant (T. aphylla) is known as "Mayyin Khurd" in Unani medicine, "Macheeka" in Ayurveda, and "Sivappattushavukku" in Siddha, among other names. T. gallica is commonly known as "Jhau" in South Asian medical traditions. In classical Persian medicine, the plant was known as "Asl," "Tarfā," and "Gaz."

1.5 Common Forms and Preparations

As a natural ingredient or traditional remedy, parts of Tamaricaceae plants are employed in multiple forms:

Bark and root-bark decoctions: The bark is historically the most commonly used part, boiled in water or wine.
Leaf decoctions and poultices: To cure wounds, abscesses, and rheumatism, the leaves are boiled in water, the water is strained, and the hot leaves are tied to the affected area.
Leaf ash preparations: As a traditional phytotherapy for jaundice, T. aphylla leaf ash is mixed with water, which is filtered and boiled; 0.5–1 g of the remaining salt is then consumed with Shurbat-e-Bazoori twice daily.
Galls: Galls formed on tamarisk plants (known as "Taknut Galls") are used in traditional preparations; these structures contain distinctive phenolic acids.
Aqueous, methanolic, and ethanolic extracts: Used in modern preclinical research, prepared by maceration or Soxhlet extraction.
Essential oils: Isolated from leaves and stems of various species.

The plant's bark, leaves, and galls have been employed in traditional remedies to address digestive issues, skin ailments, and as a general tonic. Several pharmacological activities have been demonstrated for Tamarix spp.; however, few commercial supplements have used this plant in their formulations.

2. Traditional and Historical Use

2.1 Ancient Mediterranean and Greco-Roman Use

In his "Discorsi" (1557), Pietro Andrea Mattioli, an Italian doctor and naturalist, described the properties of the "mirice" or "tamarigio," supporting the hypothesis that the name "tamarisk" has historically been attributed to shrubs that currently belong either to the Myricaria or Tamarix genera. The tamarisk shrub is also referenced in classical Greek texts: the shrub is mentioned in two books of the Iliad, in one book of the Idylls of Theocritus, in several books of the "Historia Plantarum" by Theophrastus (4th–3rd century BC), and in the "De materia medica" by Dioscorides (50–70 AD).

2.2 Persian and Unani Medicine

Tamarix spp. is one of the plants known for its medicinal properties in Persian Medicine. It was attributed a cold and dry nature with astringent and cleansing effects on internal organs, attributed to its bitter taste. It was known as a tonic for the liver and spleen, taken with vinegar.

In Unani medicine, the plant has been well-documented in classical texts. Surveys of classical Unani texts, including Khazā'in al-Adwiya, Tanqīh-al-Mufradāt, Bustān-al-Mufradāt, and Muḥīṭ-i-A'ẓam, have been conducted to document Tamarix gallica's traditional uses. Tamarix gallica is traditionally used in Unani and regional practice for leucoderma, spleen trouble, eye diseases, rheumatism, and gingivitis. Tamarix dioica, a prominent shrub from the Tamaricaceae family, is increasingly recognized in Unani medicine for its diverse benefits, including its constipative (Qabiz), retentive (Habis), anti-inflammatory, astringent, antifungal, antibacterial, hepatoprotective, and antipyretic properties.

2.3 Ayurvedic and Siddha Traditions (South Asia)

In Ayurvedic medicine, T. gallica appears in classical texts. Traditionally, Tamarix gallica has been used as an expectorant, laxative, astringent, antidiarrheal, and anti-dysentery remedy. It has broad potential covering a spectrum of illnesses such as leukoderma, eye diseases, teeth disorders, any type of hemorrhage, and spleen disorders.

Traditional preparations in these systems included root-bark, bark, leaves, seeds, and galls employed for conditions of the liver, spleen, and gastrointestinal tract. Tamarix species are employed in traditional medicine as astringent, aperitif, stimulus of perspiration, and diuretic. The plant is used as an anthelmintic, anti-haemorrhoid haemostat, and for diarrhea and gingivitis.

2.4 African Traditional Medicine

Tamarix is a native plant of African and Asian countries used by locals for medicinal purposes; it is commonly called tamarisk. Tamarisk is an edible halophyte which grows easily in a wide variety of climates, including arid areas, and is traditionally used by local people of Asian and African countries for the treatment of several ailments.

In Saudi Arabia's Asir region, for example, Tamarix aphylla is used in folkloric medicine. In Algeria and Tunisia, Tamarix africana is frequently used in traditional Algerian medicine to treat gastroduodenal problems, due to the presence of polyphenols such as phenolic acids, flavonoids, and tannins.

2.5 East Asian Traditional Medicine

The leaves of Tamarix chinensis Lour., which belongs to the family Tamaricaceae, are used as analgesic, antipyretic, antivinous, carminative, depurative, diuretic, and febrifuge.

2.6 Summary of Traditional Indications by System

Gastrointestinal: Tamarix spp. is traditionally used for gastrointestinal disorders, wounds, diabetes, and dental problems.
Hepatic and splenic: Liver and spleen disorders, jaundice, hepatitis — documented across Persian, Unani, and Ayurvedic traditions.
Skin and wounds: Wounds, eczema, leucoderma, and abscesses, through poultices and topical application.
Rheumatic and pain: The plant has been used for antirheumatic, analgesic, and antipyretic purposes throughout folk medicine.
Urinary and metabolic: It is used as a carminative diuretic in tuberculosis, leprosy, and hepatitis.
Haemostasis and gynaecological: Anti-haemorrhoid, anti-haemorrhagic, and anti-leukorrheal uses are documented in various traditions.
Neurological/Respiratory: The bark extract of Myricaria germanica has been used in folk medicine for jaundice, while infusion of the leaves was used as analgesic and was found to control chronic bronchitis.

3. Key Phytochemical Constituents and Active Compounds

3.1 Overview of Phytochemical Diversity

A comprehensive review presented a summary of 655 naturally occurring compounds derived from the genus Tamarix, categorized into flavonoids (18.0%), phenols (13.9%), tannins (9.3%), terpenoids (10.5%), essential oils (31.0%), and others (17.3%). Extensive research has been conducted on the biological activity of 30 constituents, including 15 flavonoids, 5 phenols, 3 terpenoids, 1 tannin, and 6 others.

3.2 Polyphenolic Compounds

Phenolic acids, flavonoids, and tannins constitute the main phytochemicals of Tamarix plants. The polyphenolic fraction is the most pharmacologically significant. Specific compounds identified include:

Flavonoids: Various components present in T. gallica include polyphenolic compounds such as flavonoids: naringenin, quercetin, rhamnetin, rhamnazin, tamarixetin, and kaempferol, along with phenolic acids, tannins, alkaloids, and glycosides.
Tamarixetin: A flavonoid unique to and characteristic of the genus. A floral extract of T. aphylla yielded isoferulic acid, 3-O-beta-glucopyranoside, glycosylated isoferulic acid, and novel phenolics such as dehydrodigallic acid dimethyl ester and tamarixetin 3,3'-disodium sulfate.
Key constituents of T. articulata: The major chemical constituents of the T. articulata dry leaf extract are quinic acid, gallic acid, kaempferol, quercetin, tamarixetin, epicatechin gallate, and epiafzelechin.
Sulphated flavonoids: Phytochemical investigation of Tamarix africana Poir. (Tamaricaceae) shoot polar extract yielded three new sulphated flavonoids: (2S,4R)-5,7,4'-trihydroxyflavan-4-ol 5,7-disulphate, (2S)-5,7,4'-trihydroxyflavan 7-O-sulphate, and (2S)-naringenin 4'-O-sulphate, together with ten known compounds.
Phenolic acids: Gallic acid, ellagic acid, caffeic acid, syringic acid, p-coumaric acid, isoferulic acid, vanillic acid, and para-coumaric acid are among identified phenolic acids. Gallic and ellagic acid are derivatives of T. aphylla specifically.
Tannins: Phytochemical screening of most extracts of T. aphylla has exhibited the presence of tannins and a lack of alkaloids. Hydrolyzable tannins, including ellagitannins, have been isolated from several Tamaricaceae species.
Tamarixin (Tamarixetin glycoside) and related compounds: The plant material constituted phytochemical constituents including tamarixin, tamarixetin, 4-methylcoumarin, 3,3'-di-O-methylellagic acid, and quercetol (methylic ester).

3.3 Terpenes, Steroids, and Essential Oils

Bioactive mixtures and metabolites found in T. aphylla include cardiac glycosides, flavonoids, terpenoids, and steroids. Major constituents of T. aphylla also include polyphenols, triterpenes, tamarixellagic acid, and dehydrotrigallic and dehydrodigallic acids. Essential oils form a significant fraction; the focus on antibacterial and antidiabetic effects is partly due to the presence of volatile oil and flavonoid components.

3.4 Myricaria-Specific Compounds

Phytochemical studies carried out on Myricaria plants revealed the presence of flavonoids (including rare sulfated derivatives), tannins, phenolic acid derivatives, triterpenoids, steroids, and alkanediols. From Myricaria germanica, a unique compound was isolated: tamgermanitin, a unique N-trans-Isoferuloyltyramine, together with the hitherto unknown polyphenolics, 2,4-di-O-galloyl-(α/β)-glucopyranose and kaempferide 3,7-disulphate, were isolated from the leaf aqueous ethanol extract.

3.5 Distribution Across Plant Parts

The leaves and stems of T. aphylla have a comparable phytochemical composition; however, quantitative analyses have indicated that the leaves have a considerably greater quantity of polyphenols than the stems. The leaves and stem/bark appear to be the most therapeutically effective plant parts of T. aphylla, as these parts showed several therapeutic activities.

4. Established and Proposed Mechanisms of Action

4.1 Antioxidant Mechanisms

Owing to the presence of high content of phytochemical compounds like polyphenolics and flavonoids, T. articulata is a potential source of antioxidant, anti-inflammatory, and antiproliferative properties. A high total phenolic content (151.1 mg GAE/g) was found in the methanol shoot extract of T. africana, which exhibits strong antioxidant activities using the oxygen radical absorbance capacity (ORAC) method and a skin cell-based assay. Antioxidant activity is attributable principally to the radical-scavenging behavior of phenolic hydroxyl groups in gallic acid, ellagic acid, quercetin, and related compounds.

4.2 Anti-Inflammatory Mechanisms

The shoot extract of T. africana showed significant anti-inflammatory activity, reducing nitric oxide release by 53.5% at 160 µg/mL in lipopolysaccharide-stimulated RAW 264.7 macrophages. In an in vivo study in Wistar rats: histopathology analysis revealed that Tamarix articulata extract significantly reduced hepatic fibrosis by inhibiting necrosis of hepatocytes; serum pro-inflammatory markers (tumor necrosis factor-alpha, tumor growth factor-beta, and interleukin-6) were significantly restored.

4.3 Hepatoprotective Mechanisms

The hepatoprotective effect of T. articulata extract is mostly attributed to the reduction of reactive oxygen species (ROS), which is associated with oxidative stress, restoration of serum liver biochemistry, inhibition of pro-inflammatory cytokines, and maintenance of mitochondrial membrane potential.

4.4 Anticancer Mechanisms

Six species of Tamarix have anticancer effects by causing cancer cell death, inducing autophagy, and stopping cell division. Several macrocyclic-type tannins isolated from T. nilotica showed significant cytotoxicity against carcinoma cell lines, including oral squamous cell carcinoma and promyelocytic leukemia, while demonstrating lower cytotoxicity towards normal cells.

4.5 Antidiabetic Mechanisms

Seven species from the genus Tamarix have the potential for treating diabetes by inhibiting α-glycosidase activity, suppressing human islet amyloid polypeptide, regulating blood glucose levels, and modulating autophagy or inflammation. The main component of T. gallica, tamarexin, has shown positive anti-amyloid aggregation and anti-diabetic effects.

4.6 Anticholinesterase (Neuroprotective) Mechanisms

Some Myricaria species were reported to have high antimicrobial and acetylcholinesterase inhibitory activities and thus can be considered natural sources of antibiotics and drugs for the treatment of neurological disorders such as Alzheimer's disease. At a measured concentration of 1110.00 g/mL and under assay conditions, inhibitory percentages of 21.00%, 11.20%, and 9.16% were established for AcOEt, EtOH, and MeOH leaf extracts of T. aphylla, respectively, with modest activity against AChE.

5. Scientific Evidence by Area of Use

Important note on evidence quality: The scientific literature on Tamaricaceae is dominated by in vitro (cell culture) and in vivo (animal model) preclinical studies. Preclinical pharmacological evaluations have demonstrated several biological activities for Tamarix spp., including antidiabetic, hepatoprotective, wound healing, and anti-inflammatory; however, no clinical evidence has yet been provided to support these health benefits. All findings described below, unless explicitly noted otherwise, are from preclinical research and should be interpreted accordingly.

5.1 Antioxidant Activity

Evidence level: Preclinical (in vitro) — consistently demonstrated, not validated in humans.

The antioxidant activity of T. aphylla bark was examined by assaying total phenolic content, DPPH, and hydrogen peroxide (H₂O₂) radical scavenging activity. The bark extract showed the best antioxidant effect, with an IC₅₀ value for DPPH of 18.39 ± 0.62 µg/mL. Leaves and flowers of T. gallica showed antioxidant activity; flowers showed higher antioxidant activity, with IC₅₀ values for flower extracts 1.3 (β-carotene bleaching) to 19 times (lipid peroxidation inhibition) lower than those for leaves. Flowers demonstrated the highest total phenolic content at 135.36 mg GAE/g DW.

The richness of Tamarix species in bioactive compounds may explain in part their pharmacological properties for curing a variety of illnesses associated with oxidative stress, including diabetes, cancer, and neurological pathologies.

5.2 Anti-Inflammatory Activity

Evidence level: Preclinical (in vitro and animal models) — promising; no human clinical trials.

An in vivo animal study examined the anti-inflammatory mechanisms of T. aphylla: an acute oral toxicity assay was performed through oral administration of graded doses up to 4 g/kg in Wistar rats; the carrageenan-induced edema model was used to evaluate anti-inflammatory activity; levels of TNF-α, IL-1β, COX-2, and NO inside inflamed paw tissue were measured using specific ELISA kits. Based on the acute oral toxicity assay, T. aphylla was considered generally safe, and three doses of 100, 200, and 400 mg/kg were chosen for experiments. T. aphylla expressed significant (P < 0.05) anti-inflammatory activity, showing maximum inhibition at the fifth hour at 53.47% and 70.06% at doses of 200 and 400 mg/kg respectively, compared to 63.81% for the standard drug.

5.3 Hepatoprotective Activity

Evidence level: Preclinical (animal models, in vitro) — mechanistically explored; no human data.

A PMC-indexed study investigated hepatoprotection using a CCl₄-induced hepatotoxicity model in Wistar rats: the study evaluated the hepatoprotective activity of a Tamarix articulata extract against carbon tetrachloride-mediated hepatotoxicity in Wistar rats. Oral administration of T. articulata extract at 50 mg/kg body weight significantly restored the serum levels of liver enzymes and antioxidant parameters (superoxide dismutase, catalase, glutathione reductase, and thiobarbituric reactive substances). The anti-inflammatory cytokine adiponectin levels also increased to normal levels in the group treated with T. articulata extract.

These results provide a strong platform for further evaluation of T. articulata extract as a potential agent for treating and preventing liver ailments.

5.4 Anticancer/Cytotoxic Activity

Evidence level: Preclinical (in vitro cell lines, some in vivo) — preliminary; no human trials.

A PMC study on T. articulata tested methanolic leaf extract against hepatocellular carcinoma: the methanolic extract of dry leaves of T. articulata was tested for anticancer activity against a panel of hepatocellular carcinoma cells; cell viability was determined by MTT assay after dose-dependent treatment; phase-contrast microscopy and DAPI staining served to analyze cellular and nuclear morphology; immunoblotting was performed to determine the expression of proteins associated with autophagy, apoptosis, and cell cycle. The data were described as preliminary and without a complete mechanistic study.

In Myricaria germanica, the extract, its chromatographic column fractions, and the isolated isoferuloyltyramine tamgermanetin demonstrated potential cytotoxic effect against three different tumor cell lines — liver (Huh-7), breast (MCF-7), and prostate (PC-3) — with substantially low IC₅₀ values and low-resistance possibility.

For T. nilotica, previous research found that Tamarix nilotica butanolic fractions showed promising anticancer activity against liver cancer cell Huh-7 with IC₅₀ = 37 µg/mL.

5.5 Antidiabetic Activity

Evidence level: Preclinical (in vitro enzyme inhibition, animal models) — promising; no human clinical trials.

Seven species from the genus Tamarix have the potential for treating diabetes by inhibiting α-glycosidase activity, suppressing human islet amyloid polypeptide, regulating blood glucose levels, and modulating autophagy or inflammation. Flavonoids, specifically O-methylated and glucuronosylated derivatives found in T. gallica, have been investigated for α-glucosidase inhibitory activity, a key mechanism relevant to post-prandial blood glucose control.

5.6 Antimicrobial Activity

Evidence level: Preclinical (in vitro) — consistently demonstrated across multiple species; not validated clinically.

Several studies have demonstrated antioxidant and antimicrobial activities of Tamarix species, such as T. ramosissima. Nonclinical studies have shown that T. aphylla has significant antimicrobial, antioxidant, and cytotoxic activities. The antimicrobial activity is attributed principally to polyphenolic compounds and essential oil constituents.

5.7 Wound Healing

Evidence level: Preclinical (animal models and in vitro); traditional use well-documented.

Wound healing activity is a consistently reported property for multiple Tamarix species in preclinical models. Various pharmacological properties shown by T. aphylla include antidiabetic, anti-inflammatory, antibacterial, antifungal, anticholinesterase, and wound-healing activity. The tannin content is believed to contribute to wound-sealing and antimicrobial properties that underlie this effect.

5.8 Gastroprotective / Anti-Ulcer Activity

Evidence level: Single preclinical animal study; limited data.

A PMC study evaluated T. gallica flower extract against aspirin-induced peptic ulcers in rats: because scientific evidence based on efficacy specifically for anti-ulcer activity was limited, the study aimed to evaluate the protective effect of T. gallica (TG) against aspirin-induced peptic ulcers; phytochemical screening was performed followed by assessment in rats. Network biology and polypharmacology studies were performed to determine possible molecular targets. The study revealed that TG extract at high dose (500 mg/kg b.w.) significantly exhibited protective effect against aspirin-induced ulcers via regulation of free acidity and pepsin production.

5.9 Neuroprotective / Anticholinesterase Activity

Evidence level: In vitro only; very early-stage research.

Studies on the extracts and compounds isolated from Myricaria species demonstrated various biological activities, including antioxidant, anti-inflammatory, cytotoxic, antimicrobial, analgesic, antinociceptive, cholinergic, and glucose absorption reducing properties. These findings are exclusively based on in vitro models and require substantial further investigation.

5.10 Summary Statement on Clinical Evidence

Clinical trials establishing the health benefits were not found for T. aphylla; therefore, high-quality preclinical studies and well-designed clinical studies are needed to confirm the efficacy and safety of T. aphylla in people. This conclusion is broadly applicable across the genus. Tamarix spp. are plants rich in polyphenolic compounds with valuable medicinal properties; however, there are several methodological problems such as lack of a mechanistic approach and taxonomic ambiguities in current available data. High-quality preclinical studies as well as well-designed clinical trials are necessary to confirm the safety and efficacy of these plants in humans.

6. Body Systems and Associated Health Areas

Based on the totality of traditional use and preclinical evidence, Tamaricaceae plants are associated with the following body systems:

Hepatobiliary system: Liver protection, anti-fibrotic effects, jaundice, hepatitis — the most extensively studied area preclinically.
Gastrointestinal system: Diarrhea, dysentery, peptic ulcer, constipation, anthelmintic activity, spleen disorders.
Immune / Inflammatory system: Modulation of TNF-α, IL-1β, COX-2, and NO pathways; anti-inflammatory effects in rheumatic and inflammatory conditions.
Metabolic / Endocrine system: Blood glucose regulation, α-glucosidase inhibition, anti-hyperlipidemic activity.
Integumentary system: Wound healing, eczema, leucoderma, skin infections, galls used as topical remedies.
Oncology (preclinical): Cytotoxicity against liver, breast, prostate, and leukemia cell lines in in vitro settings.
Neurological system (very early-stage): Acetylcholinesterase inhibition potentially relevant to Alzheimer's disease.
Renal / Urinary system: Diuretic, anti-nephrolithiasis uses documented in traditional systems.
Dental / Oral health: Traditional use for gingivitis and dental disorders, consistent with antimicrobial and astringent properties.
Respiratory system: Historical use in tuberculosis; bronchitis management attributed to Myricaria germanica.

7. Dosage Forms and Reported Dosages

There are no established human clinical dosages for Tamaricaceae-derived preparations, as no clinical trials have been completed. The following dosages are as reported in preclinical studies and traditional sources only:

Anti-inflammatory animal studies (T. aphylla): Based on the acute oral toxicity assay, T. aphylla was considered generally safe and three different doses of 100, 200, and 400 mg/kg were chosen for further anti-inflammatory experiments.
Hepatoprotective animal study (T. articulata): Oral administration of T. articulata extract at 50 mg/kg body weight significantly restored the serum levels of liver enzymes and antioxidant parameters.
Anti-ulcer animal study (T. gallica): TG extract at high dose (500 mg/kg b.w.) significantly exhibited protective effect against aspirin-induced ulcers.
Traditional Unani preparation (T. aphylla): Leaf ash is mixed with water, filtered and boiled; 0.5–1 g of the remaining salt is consumed with Shurbat-e-Bazoori twice daily.

All animal doses above are expressed as mg/kg body weight and cannot be directly extrapolated to human dosing without appropriate pharmacokinetic bridging studies. No standardized extract dosages have been validated in human clinical trials.

8. Safety Considerations

8.1 Acute Oral Toxicity — Animal Data

Studies reported that the LD₅₀ of T. aphylla is above 1500 mg/kg body weight, and the methanolic extract produced no toxic symptoms in graded doses up to 4000 mg/kg in acute and sub-chronic toxicity studies. Based on OECD guidelines for testing chemicals, the methanolic extract of T. aphylla was considered safe.

Methanolic and ethyl acetate extracts of Tamarix gallica showed no mortality after acute oral toxicity studies up to a dose of 3000 mg/kg body weight in albino rats. Similarly, T. gallica is considered relatively safe at a dose of up to 3000 mg/kg body weight in an acute oral toxicity study.

The findings of many studies indicate that the leaf extract of T. aphylla is nontoxic with no reported mortality, while toxicity of T. aphylla was found to be negligible in studies from Saudi Arabia and Pakistan.

8.2 Limitations of Current Safety Data

Clinical trials establishing the health benefits were not found; therefore, high-quality preclinical studies and well-designed clinical studies are needed to confirm the efficacy and safety of T. aphylla in people. Herbal supplements have not received the same scientific scrutiny and are not as strictly regulated as medications. Natural products are regulated by the US Food and Drug Administration (FDA), but not as strictly as prescription or over-the-counter (OTC) drugs.

8.3 Lack of Human Safety and Interaction Data

One of the reasons for the limited use of Tamarix spp. is the lack of clinical studies on the therapeutic and toxicological profile. No documented drug-herb interaction studies in humans have been published. Given the significant content of tannins, flavonoids, and phenolic acids — compound classes known to interfere with iron absorption, drug bioavailability, and cytochrome P450 enzymes in other botanical contexts — caution is warranted, though no species-specific interaction data are available in the current literature for Tamaricaceae preparations.

8.4 Pollen Allergy Risk

Tamarisk species are known to be prolific pollen producers and their pollen is an established aeroallergen in regions where they grow. However, this is not relevant to ingested supplement preparations.

8.5 Invasive Species Concerns Affecting Supply Quality

Tamarix species' growth in wet climates is not desired, as they act as invasive plants which can prevent the growth of other species. This ecological context means that wild-harvested material collected from invasive populations may have variable phytochemical composition depending on soil and environmental conditions, potentially affecting consistency in supplement preparations.

8.6 Absence of Regulatory Monographs

At the time of the available literature, no official pharmacopoeial monograph (European Pharmacopoeia, USP, WHO monograph, ESCOP, or German Commission E) specifically covers Tamaricaceae species as standardized dietary supplement ingredients. This limits quality control benchmarks for commercial preparations.

9. Overall Evidence Assessment

The Tamaricaceae family — particularly the genus Tamarix — represents a botanically and phytochemically rich group of plants with a deep cross-cultural history of medicinal use. A considerable number of species in this genus are used as traditional medicines to treat various human diseases, especially in Asian and African countries. A comprehensive summary of 655 naturally occurring compounds has been catalogued; the investigation revealed that the crude extracts and phytochemicals of this genus exhibited significant therapeutic potential, including anti-inflammatory, anti-Alzheimer, anticancer, antidiabetic, antibacterial, and antifungal activities.

Despite this promise, the evidence base remains firmly in the preclinical domain. The body of published research consists almost entirely of in vitro cell assays and small animal studies. No peer-reviewed, randomized, controlled clinical trials in humans have been identified for any Tamaricaceae-derived preparation used as a dietary supplement. Future research should thoroughly study the mechanisms of action of the identified compounds. The field also faces challenges from methodological problems such as lack of a mechanistic approach and taxonomic ambiguities in the current available data.

References

Health Conditions

Health conditions that Tamaricaceae may help support.

No conditions available.

Body Systems

Body systems that Tamaricaceae may help support.

No body systems available.